Replies to post #139852 on Biotech Values

[oc631]

I am hopeful that any positive results from the GS-7977/TMC435 combo trial will be enough to get Medivir shares moving, irrespective of GILD's ultimate plans, which is why I'm long Medivir. We shall see.

If GS-7977/Riba lacks potency in GT1 GILD would have to re-calculate approval dates for a new in-house combo*. They have several classes of drugs in mid-stage testing to chose from. If GILD did decide to partner a late stage drug I suspect it would be TMC-435 (considering comparable results to the NS5A combo). BMY has the pipeline to develop an in-house oral combo and is in a stronger bargaining position than Tibotec.


*Note: I'm not saying this is going to happen.